Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 1 of 3 (33%) have an AI response strategy ready
Csl Behring Lengnau AG manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 2 pending office actions currently active. These actions are distributed among 2 distinct examiners, which indicates that each pending matter is being handled by a different individual at the patent office.
The prosecution activity is spread across 2 distinct art units, matching the 2 distinct examiners involved. YUNSOO KIM is identified as the busiest examiner for the portfolio, with 1 busiest examiner pending office action. Given that there are 2 pending office actions in total, the busiest examiner is responsible for 1 of the 2 pending office actions.
This distribution across 2 distinct art units suggests that the company's patent applications may cover different technical sub-fields within Biotechnology & Pharmaceuticals. Practitioners should be prepared to navigate 2 different examination environments, as each of the 2 distinct examiners will bring their own perspective to the 2 pending office actions. The presence of YUNSOO KIM as a primary contact for 1 of these actions provides a specific point of focus for the company's legal strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| MULDER, SCOTT EVAN | 1 | 41.2% | +65.2% |
| ZINGARELLI, SANDRA | 1 | 6.9% | +46.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17623398 | A TRUNCATED VON WILLEBRAND FACTOR (VWF) FOR INCREASING THE IN VITRO STABILITY OF COAGULATION FACTOR VIII | ZINGARELLI, SANDRA | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17775704 | POLYPEPTIDES FOR INDUCING TOLERANCE TO FACTOR VIII | MULDER, SCOTT EVAN | 113d overdue |
| 17623398 | A TRUNCATED VON WILLEBRAND FACTOR (VWF) FOR INCREASING THE IN VITRO STABILITY OF COAGULATION FACTOR VIII | ZINGARELLI, SANDRA | 23d overdue |
| 17782404 | STABLE COMPOSITIONS OF FC MULTIMERS | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1656 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17782404 | STABLE COMPOSITIONS OF FC MULTIMERS | KIM, YUNSOO | 1641 | §103 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17775704 | POLYPEPTIDES FOR INDUCING TOLERANCE TO FACTOR VIII | MULDER, SCOTT EVAN | 1656 | §103 | Non-Final OA | 113d overdue | AI Ready | May 10, 2022 |
| 17623398 | A TRUNCATED VON WILLEBRAND FACTOR (VWF) FOR INCREASING THE IN VITRO STABILITY OF COAGULATION FACTOR VIII | ZINGARELLI, SANDRA | 1653 | §102§103§112 | Final Rejection | 23d overdue | Pending | Dec 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial